Asahi Kasei Pharma Corporation

[On Demand]

Asahi Kasei Pharma Corporation (AKP), headquartered in Tokyo, Japan, is a fully integrated pharmaceutical company with capabilities in R&D, manufacturing and commercialization.  AKP has successfully partnered with large and small organizations to develop and commercialize a variety of innovative treatments including Famvir, Flivas, Toledomin, Xiaflex, Reclast and Kevzara as well as our own original products such as Teribone and Recomodulin. AKP has a well-established record of managing clinical trials and successfully obtaining product marketing approvals in Japan.

AKP is currently pursuing attractive new in-licensing and research collaboration opportunities in the following therapeutic areas.

  • Area of Interests: Pain management, Musculoskeletal disorders, Autoimmune diseases, Critical care medicine, and Rare diseases.

Company Type:
Publicly Traded Company
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
AK1820 (Isavuconazole)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Primary Executive Officer, Head of R&D and BD
Asahi Kasei Pharma Corporation